Fruquintinib Dosage
The recommended dosage of fruquintinib is 5 mg orally once daily for 21 consecutive days, followed by 7 days off, in repeating 28-day cycles 1, 2.
Standard Dosing Regimen
- Dose: 5 mg orally once daily
- Schedule: Days 1-21 of each 28-day cycle (3 weeks on/1 week off)
- Administration: Take with or without food 2
- Continue until: Disease progression or unacceptable toxicity 2
This dosing recommendation is consistent across multiple international guidelines, including the 2025 Chinese Society of Clinical Oncology (CSCO) guidelines 1 and the 2024 NCCN guidelines 3, and is supported by the FDA-approved label 2.
Dose Modifications for Toxicity
While the evidence provided does not include a complete dose modification table from the FDA label, the following principles apply:
Key Management Strategies:
- Grade ≥3 adverse events: Dose reductions are commonly needed for hypertension (10.7% of patients), hand-foot syndrome (6.1%), and proteinuria 4
- Most common reasons for dose reduction: Hand-foot syndrome (5.0%), hypertension (2.9%), and proteinuria (1.3%) 4
- Discontinuation rate: Only 5.9% of patients discontinued due to treatment-related adverse events 4
The standard dose reduction sequence would typically be from 5 mg to 4 mg to 3 mg, though specific reduction protocols should follow institutional guidelines or FDA labeling.
Alternative Dosing Strategy for Elderly Patients
For patients ≥65 years with reduced tolerance, a dose-escalation approach may be considered 5:
- Week 1: Start at 3 mg once daily
- Week 2: Escalate to 4 mg once daily (if no significant toxicity)
- Week 3: Escalate to 5 mg once daily (if no significant toxicity)
- Subsequent cycles: Continue at the highest tolerated dose from Cycle 1
This approach showed that 51.7% of elderly patients tolerated 4 mg and only 13.8% reached the full 5 mg dose, with a median PFS of 3.8 months and median OS of 7.6 months 5. However, this remains investigational and is not the standard FDA-approved approach.
Special Populations
No dose adjustment required for:
- Age 18-82 years 2
- Mild renal impairment (CrCl 15-89 mL/min) 2
- Mild hepatic impairment (total bilirubin ≤ULN with AST >ULN, or bilirubin 1-1.5× ULN with any AST) 2
Not recommended for:
- Severe hepatic impairment (total bilirubin >3× ULN with any AST) 2
Insufficient data for:
- Moderate to severe hepatic impairment (total bilirubin >1.5× ULN with any AST) 2
Drug Interactions
Avoid strong CYP3A inducers (e.g., rifampin), which decrease fruquintinib exposure by 65% 2. If unavoidable, consider dose adjustment, though specific recommendations are not provided in the available evidence.
No dose adjustment needed with:
Clinical Context
Fruquintinib is indicated for metastatic colorectal cancer that has progressed through all other available regimens, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, anti-VEGF therapy, and (if RAS wild-type) anti-EGFR therapy 3. It can be given before or after trifluridine-tipiracil or regorafenib, with no data to inform optimal sequencing 3.
The drug demonstrated a median OS of 7.4 months versus 4.8 months with placebo in the FRESCO-2 trial, with a manageable safety profile where only 20% discontinued due to toxicities 3.